Heart Valve Disease: TAVR Expansion to Lower-Risk and Younger Patients
Sam Anderson
The TAVR Evolution: From High-Risk to Low-Risk
Transcatheter aortic valve replacement has expanded rapidly from a last resort for inoperable patients to a first-line option for many patients with severe aortic stenosis across the risk spectrum. For the cardiologist, cardiac surgeon, or internist managing patients with valvular heart disease, the clinical decision is no longer whether TAVR works — that question has been answered definitively — but which patients are best served by TAVR versus surgical valve replacement, and how to navigate the emerging data on valve durability, conduction disturbances, and expanding indications.
TAVR for severe aortic stenosis progressed through four risk tiers in landmark trials: PARTNER 1B (inoperable, 2010), PARTNER 1A/CoreValve Extreme Risk (high-risk, 2011-2014), PARTNER 2A/SURTAVI (intermediate-risk, 2016-2017), and PARTNER 3/Evolut Low Risk (low-risk, 2019). In PARTNER 3, TAVR with the SAPIEN 3 valve demonstrated a lower rate of the composite primary endpoint (death, stroke, or rehospitalization) at 1 year: 8.5% versus 15.1% for SAVR (HR 0.54, 95% CI 0.37-0.79, p = 0.001)[1]. The Evolut Low Risk trial showed TAVR non-inferiority to surgery for the composite of death or disabling stroke at 24 months (5.3% vs 6.7%)[2].
Durability: The Critical Unknown for Younger Patients
Transcatheter valve durability data remain limited beyond 5-8 years. Five-year data from PARTNER 2A show structural valve deterioration (SVD) in approximately 2-3% of TAVR valves[3], comparable to surgical bioprosthetic valves at the same timeframe. However, mechanical stress modeling and accelerated wear testing suggest that TAVR valves may have shorter functional lifespans than surgical bioprostheses due to non-circular deployment geometry and residual stress on leaflets. For patients with life expectancy exceeding 10-15 years, this durability uncertainty is the primary argument for continued surgical referral. The 2024 ACC/AHA valvular heart disease guidelines recommend shared decision-making with a heart valve team and emphasize that SAVR remains preferred for patients under age 65 given durability concerns.
Bicuspid Aortic Valve: An Expanding Frontier
Bicuspid aortic valve (BAV), present in approximately 50% of patients with severe AS under age 70, was excluded from pivotal low-risk trials. BAV anatomy presents technical challenges: asymmetric calcification, larger annular dimensions, and higher rates of paravalvular leak. Retrospective registries and the BAVARD study suggest contemporary TAVR in BAV achieves acceptable outcomes in experienced centers, with procedural success exceeding 95% using newer-generation self-expanding and balloon-expandable valves. However, concomitant aortopathy requiring surgical intervention (ascending aortic diameter above 4.5 cm) remains a contraindication to isolated TAVR.
Transcatheter Mitral and Tricuspid Interventions
The COAPT trial demonstrated that transcatheter edge-to-edge repair (MitraClip) reduced heart failure hospitalizations by 47% and all-cause mortality by 38%[4] in patients with severe secondary mitral regurgitation despite optimized GDMT. Patient selection is critical: the COAPT eligibility criteria (effective regurgitant orifice area above 0.3 cm2, LVEDV below 200 mL, LVEF 20-50%)[4] define a disproportionate MR population that benefits. For tricuspid regurgitation, the TriClip (TRILUMINATE Pivotal) demonstrated superiority over medical therapy for TR reduction, though mortality and heart failure hospitalization benefits at 1 year did not reach significance[5]. The transcatheter tricuspid field remains earlier in development compared to aortic and mitral interventions.
Lifetime Management and the Heart Valve Team
For patients with severe AS, the initial valve intervention decision must consider the entire lifetime trajectory. A 50-year-old patient may require 2-3 valve interventions over their lifetime, making the sequence of procedures critical. Valve-in-valve TAVR for degenerated surgical bioprostheses achieves excellent outcomes when the original surgical valve is 23 mm or larger, but small surgical valves (19-21 mm) risk patient-prosthesis mismatch with TAV-in-SAV. This lifetime planning, weighing initial TAVR convenience against potential future limitations, underscores the importance of multidisciplinary heart valve team assessment for all patients, particularly those under 75. Concurrent atrial fibrillation and stroke prevention must also be addressed in the periprocedural period.
Limitations and the Durability Question
The central unresolved question in structural heart intervention is long-term valve durability. The trials that established TAVR's safety and efficacy in low-risk patients have follow-up measured in years, while the patients being treated increasingly have life expectancies measured in decades. If transcatheter valves degenerate faster than surgical bioprostheses, the short-term procedural advantages of TAVR may be offset by the need for earlier reintervention — and valve-in-valve procedures, while feasible, add complexity and carry their own risk of patient-prosthesis mismatch in small annuli. Until long-term durability data mature, the recommendation to preferentially refer younger patients (under 65) for surgical AVR reflects appropriate caution rather than therapeutic conservatism. The next decade of follow-up data from the low-risk trials will either confirm or challenge this approach, and the field should be prepared to update recommendations as the evidence evolves.
References
- Mack MJ, et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients (PARTNER 3). PubMed 30883058
- Popma JJ, et al. Self-Expanding Transcatheter Aortic Valve Replacement vs Surgical Aortic Valve Replacement in Low-Risk Patients (Evolut Low Risk). PubMed 30883053
- PARTNER 2A 5-year follow-up: TAVR vs SAVR in Intermediate-Risk Patients. PubMed 30946473
- Stone GW, et al. Transcatheter Mitral-Valve Repair in Patients with Heart Failure (COAPT). PubMed 30134187
- TRILUMINATE Pivotal: Transcatheter Tricuspid-Valve Repair for Tricuspid Regurgitation. PubMed 39471883
Frequently Asked Questions
What did PARTNER 3 show for TAVR vs SAVR in low-risk patients?
Is TAVR recommended for patients under 65 with severe aortic stenosis?
Can TAVR be performed for bicuspid aortic valve stenosis?
What were the COAPT trial results for transcatheter mitral repair?
What is the valve-in-valve TAVR success rate for failed bioprostheses?
What is the structural valve deterioration rate for TAVR at 5 years?
What did TRILUMINATE show for transcatheter tricuspid repair?
Explore This Topic in Ailva
Ailva is a free clinical intelligence platform for NPI-verified US physicians. Get evidence-based answers with verified citations from 16M+ indexed papers — plus free CME credits.
Founder of Ailva.ai | Former Director of Research and Author of 200+ Medically Reviewed Articles | Editor-in-Chief of EudaLife Magazine